Linking alpha1-antitrypsin phase transition with cellular health

点击翻译按钮获取中文摘要

Alpha1-antitrypsin is a protein made in the liver that circulates in the blood to control inflammation in the lungs. Some people with a condition call alpha1-antitrypsin deficiency are at increased risk of liver and lung disease because they have inherited a mutated form of alpha1-antitrypsin that accumulates in liver cells and fails to reach the blood. This abnormal antitrypsin, builds up inside a part of the cell called the endoplasmic reticulum (or ER for short). This build-up then increases the risk of liver cirrhosis (scarring) and liver cancer. No current treatments apart from liver transplantation can help in this form of liver disease. We study the accumulation of alpha1-antitrypsin inside the ER so that we can develop new liver-protective treatments.Many human diseases can arise when the ER malfunctions: so-called ER stress. The job of the ER is to make secreted proteins, like antitrypsin, allowing newly made proteins to "fold" into their unique shape that allows them to perform their specific roles in the body. ER stress happens when ER proteins fail to fold correctly, which can happen with some mutated proteins. This causes ER proteins to stick together randomly, damaging the cell. By contrast, the most common mutated form of alpha1-antitrypsin forms ordered chains of polymers that do not appear to cause ER stress directly. Instead, they make the cell more sensitive to other stresses, such as saturated fats or alcohol, which can trigger ER stress more easily. The reason why polymers of antitrypsin cause this increased sensitivity is unknown, but we recently discovered that antitrypsin polymers can solidify inside the ER to forming a porous material that traps large ER proteins while allowing smaller ones to pass through. This "molecular filtration" may prevent large ER proteins moving to where they are required and this may account for the increased sensitivity to ER stress. Importantly, we discovered that some proteins in the ER drive this solidification of antitrypsin and can be prevented from doing so by blocking certain signalling pathways inside the cell.In the current project, we aim to identify which cellular proteins are responsible for the solidification of antitrypsin. We will also determine how the solidification of antitrypsin affects the health of cells. Finally, we will use this knowledge to develop therapies to protect liver cells from the toxic effects of alpha1-antitrypsin mutations.